Company intelligence / Profile preview

ThioMatrix

Innsbruck, Tirol, Austriathiomatrix.com ↗

Ownership: Private
Development stage: Preclinical

Overview

ThioMatrix develops proprietary non-invasive drug delivery technologies—primarily the Thiomer and SEDDS platforms—to enhance the bioavailability of orally administered peptides, proteins, and small molecules. In vivo studies have demonstrated significant improvements in oral bioavailability for class III drugs using these approaches. The company collaborates with academic institutions, CROs, hospitals, and industry partners to advance its technologies from preclinical through clinical stages.

Therapeutic areas: Metabolic Disorders
Modalities: PeptidesProteinsSmall molecule (via SEDDS)
Industry: Biotech

Partnerships

EU-project TENTACLE consortium for bioprinting applications using thiomers

Beyond the preview

Go deeper on ThioMatrix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ThioMatrix.

Explore the full profile